How peptides can reach the brain through the nose: the olfactory route explained

The olfactory nerve is a physical gap in the blood-brain barrier. What nose-to-brain research has measured in people and in preclinical studies, why the human numbers are smaller, and what remains unknown.

Published · Updated · 9 min read
TL;DR
  • Olfactory neurons run from the lining of the nose straight into the brain's olfactory bulb, so a molecule can travel along them without crossing the blood-brain barrier at the point of entry.
  • A 1996 human study found intranasal vasopressin changed a brain electrical signal (P300) that intravenous vasopressin did not.
  • In humans, the olfactory epithelium covers under 5% of the nasal surface, against 40 to 50% in the preclinical species most nose-to-brain studies use, so preclinical brain-delivery ratios overstate what happens in people.
  • Two nerve routes carry material from the nose: the olfactory route toward the olfactory bulb, hippocampus and cortex, and the trigeminal route toward the brainstem.
  • Semax and Selank were developed as nasal products in Russia; for most other research peptides, nose-to-brain delivery has not been measured in people.

In 1996, researchers in Germany gave healthy volunteers intranasal vasopressin and watched a brain electrical signal called the P300 change on EEG. Then they gave the same volunteers intravenous vasopressin. The signal changed with the nasal route and not with the intravenous one. Same molecule, same people, different route. That experiment is one of the clearest pieces of human evidence for a nose-to-brain pathway, and it is the subject of this page. This is pharmacology education, not a guide to using any nasal product.

20x

Brain-versus-periphery targeting advantage of intranasal over intravenous delivery reported for galanin-like peptide (GALP) in preclinical pharmacokinetic work; for exendin, a GLP-1 agonist, the figure was 4x. The size of the advantage depends on how poorly the peptide crosses the blood-brain barrier on its own. Source: Meredith, Salameh and Banks, AAPS Journal, 2015 (PMC4476983).

The olfactory shortcut

How can a molecule reach the brain without entering the bloodstream?

The blood-brain barrier is a layer of tightly joined cells lining every capillary in the brain. Most drugs cannot cross it, and most peptides cannot either, because their size and water solubility rule out passive diffusion and the barrier has no transporter for most of them.

The olfactory pathway is the exception. Olfactory neurons have one end in the lining of the upper nose and the other in the olfactory bulb of the brain, passing through small perforations in the cribriform plate of the skull. A molecule moving along the space around these nerve fibres does not need to cross a tight junction to get in. A 2022 review in Pharmaceutics (Alabsi et al., PMC9502087) described brain access along this extracellular route within about 30 minutes.

In plain English

Think of the olfactory nerve as a service tunnel running under a security checkpoint. It was built to carry smell signals from the nose to the brain, but it is a physical gap in the barrier. Molecules that reach the right patch of tissue in the nose can use it. Molecules absorbed anywhere else in the nose go into the blood and face the barrier like any other drug.

Why the human numbers are smaller than the headlines

The nasal cavity's total lining covers roughly 150 to 180 square centimetres, but the olfactory epithelium, the only part containing olfactory neurons, covers less than 5% of it in humans. It sits high and far back in the nose. The rest is respiratory lining; a peptide absorbed there enters the blood and has to cross the blood-brain barrier like an injected drug.

In the species used for most preclinical nose-to-brain studies, the olfactory epithelium covers 40 to 50% of the nasal surface. Crowe and Hsu's 2022 review in Pharmaceutics (PMC8950509) identified this anatomical difference as a primary reason preclinical results vary so much from human outcomes. A headline figure for brain delivery usually comes from preclinical work and does not transfer directly to people.

5%

Human olfactory epithelium as a share of total nasal lining, against 40 to 50% in the preclinical species used for most nose-to-brain studies. Source: Crowe and Hsu, Pharmaceutics, 2022 (PMC8950509).

Two pathways

The olfactory and trigeminal routes go to different places

The olfactory nerve is not the only nerve in the nose. The trigeminal nerve supplies much of the nasal lining, including the front of the cavity, and offers a second direct route with different destinations.

Olfactory route (cranial nerve I)

Starts in the upper rear nasal vault. Leads toward the olfactory bulb and from there to regions including the hippocampus, prefrontal cortex and amygdala.

Trigeminal route (cranial nerve V)

Starts in the front of the nasal lining and the septum. Leads toward the brainstem, pons and cerebellum, regions involved in breathing, heart rate and pain modulation.

Formulation affects which route dominates. A 2021 paper in Pharmaceutics (Kamei et al., PMC8618983) showed that adding a cell-penetrating peptide to an intranasal formulation shifted distribution toward the olfactory bulb in preclinical work. Clinical nasal drug trials use standardised devices for the same reason: delivery to the upper nasal vault is hard to achieve consistently.

"Intranasal vasopressin produced a significant increase in P3 event-related potential amplitude in healthy subjects. Intravenous vasopressin [...] produced no consistent effect on brain electrical activity. These findings provide direct functional evidence for a nose-to-brain pathway for peptide effects in humans that is not accessible through the intravenous route."

Pietrowsky, Struben, Molle, Fehm and Born, Biological Psychiatry, 1996

Human trials of nose-to-brain delivery

The largest human research program is intranasal insulin for cognitive disorders. A phase 2 study at Wake Forest (NCT05081219) testing intranasal insulin in Alzheimer's disease, completed in September 2024, used a device designed to deliver to the upper nasal vault and reported results on the ADAS-Cog13 cognitive scale. Insulin is a peptide hormone and an approved drug for diabetes; intranasal insulin is not approved for any cognitive use.

Among the peptides on this site, Semax and Selank were developed as nasal products and registered in Russia, and their clinical studies used the intranasal route. For most other research peptides, nose-to-brain delivery has not been measured in people at all. Preclinical work has reported rapid brain effects after intranasal Epithalon, and there is no published human pharmacokinetic data for intranasal BPC-157 or Dihexa.

Does the nasal route bypass the blood-brain barrier entirely?

Partly. The olfactory route avoids the barrier at the entry step, from nose to olfactory bulb. From there, compounds spread into nearby brain regions through the fluid between cells. The barrier still lines every brain capillary, so a molecule that leaves the brain tissue into the blood, or arrives from the blood, faces it as usual.

Olfactory function also varies between people. The density of olfactory neurons declines with age, and chronic rhinitis and smoking reduce the available tissue. That variation is one more reason delivery through the nose is less predictable than delivery into the blood.

What genetics does and does not tell you here

No study has linked any genetic variant to how much of a peptide reaches the brain through the nose. BDNF Val66Met and COMT Val158Met come up in discussions of nasal peptides like Semax because of their proposed effects on BDNF and dopamine, but no study has tested whether either genotype changes response to an intranasal peptide.

The bottom line

The nose-to-brain route is real, and smaller in people than in preclinical studies.

Human evidence such as the 1996 vasopressin study and the intranasal insulin trials shows the pathway exists. The olfactory tissue it depends on is a small target in humans, and for most research peptides nobody has measured how much reaches the brain. For the wider picture of peptide absorption, see oral peptide bioavailability.

ShareXLinkedIn
Your DNA reportSee how your DNA reads the peptides in this guide.Your report reads the DNA file you already have against the published research on 31 peptides, marker by marker, and says what that research does and does not show. Checked by our team, ready within 24 hours.Upload your DNA, $99No DNA test yet? Order one →

Frequently asked questions

How can intranasal peptides reach the brain?

Olfactory neurons run from the lining of the upper nose directly into the brain's olfactory bulb. Molecules that reach that tissue can travel along the space around the nerve fibres into the brain without crossing the blood-brain barrier at the point of entry. Molecules absorbed elsewhere in the nose enter the blood instead.

What is the human evidence for nose-to-brain delivery?

A 1996 study (Pietrowsky et al., Biological Psychiatry) found intranasal vasopressin changed the P300 brain signal in healthy volunteers while intravenous vasopressin did not. Intranasal insulin has been tested in Alzheimer's disease trials, including a phase 2 study at Wake Forest (NCT05081219) completed in 2024.

Why do preclinical nose-to-brain results overstate what happens in people?

In humans the olfactory epithelium covers less than 5% of the nasal lining, against 40 to 50% in the preclinical species most studies use. Crowe and Hsu's 2022 review identified this difference as a primary reason preclinical brain-delivery results vary from human outcomes.

Do intranasal peptides bypass the blood-brain barrier completely?

Partly. The olfactory route avoids the barrier at the entry step, from nose to olfactory bulb. Once inside, compounds spread through the fluid between brain cells, and the barrier still lines every brain capillary.

Has nose-to-brain delivery been measured for research peptides?

Mostly not. Semax and Selank were developed and studied as nasal products in Russia. For most other research peptides, including BPC-157 and Dihexa, there is no published human pharmacokinetic data for the intranasal route.

This article is for informational and educational purposes only. It reports what published research found; it is not medical advice, it does not diagnose, treat, cure or prevent any disease, and nothing in it is a dose or a recommendation to use any compound. Talk to a licensed clinician about any medical decision.

Keep reading

Related articles

Comparisons & ReviewsSemax vs Selank: two Russian peptides, two different mechanisms, and what the research shows10 min readHow It WorksOral peptide bioavailability: less than 1% makes it out alive10 min read
← PreviousThe gut-liver axis: what preclinical studies of BPC-157 and GLP-2 foundHow It Works · 9 min readNext →The IGF-1 to IGFBP-3 ratio explained: what it shows that total IGF-1 does notHow It Works · 9 min read
Upload your DNA